ASCLF (Ascletis Pharma) Total Debt per Share: $0.00 (As of Dec. 2025)

What is Ascletis Pharma Total Debt per Share?

Ascletis Pharma ASCLF -4.00% 38 Total Debt per Share is $0.00 as of Dec. 2025. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review.

$0.00 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Ascletis Pharma's Total Debt Per Share for the quarter that ended in Dec. 2025 was $0.00.

Ascletis Pharma Total Debt per Share Related Terms

Ascletis Pharma Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Ascletis Pharma's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascletis Pharma Total Debt per Share Chart

Ascletis Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Debt per Share

Get a 7-Day Free Trial

0.00

Ascletis Pharma Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Total Debt per Share	Get a 7-Day Free Trial														0.00	0.00	0.00	0.00	0.00

38GF Score

Ascletis Pharma Inc ASCLF

Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Ascletis Pharma Total Debt per Share Calculation

Ascletis Pharma's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.33	+	0.41)	/	986.09
	=	0.00

Ascletis Pharma's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.33	+	0.41)	/	986.09
	=	0.00

Frequently Asked Questions Learn more about Total Debt per Share →

What does a Total Debt per Share of $0.00 mean?

Ascletis Pharma (ASCLF) has a Total Debt per Share of $0.00 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Ascletis Pharma and its competitors.

Is Ascletis Pharma's Total Debt per Share too high?

Ascletis Pharma's current Total Debt per Share is $0.00. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Ascletis Pharma's Total Debt per Share compare to VRTX and REGN?

Ascletis Pharma's Total Debt per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Debt per Share for a Biotechnology company?

A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Debt per Share mean?

A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Ascletis Pharma and its competitors. Ascletis Pharma's current Total Debt per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Ascletis Pharma stock overvalued right now?

Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current Total Debt per Share is $0.00. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Debt per Share calculated?

Total Debt per Share is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Total Debt per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ascletis Pharma (ASCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued. The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02. GuruFocus considers Ascletis Pharma to be Significantly Overvalued.

Key valuation signals for ASCLF:

Total Debt per Share: $0.00
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ascletis Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies HKSE:02595 HKSE:09887 HKSE:02142 HKSE:01779 HKSE:01952 HKSE:02335 HKSE:02171 HKSE:06855 HKSE:06938 HKSE:02616 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges 01672:Hong Kong 2VJ:Germany

Address No. 248 Queen’s Road East, 40th Floor, Dah Sing Financial Centre, Wanchai, HKG, 311200

Website https://www.ascletis.com

Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.

38GF Score

Get the complete analysis for ASCLF

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.44

Price

$0.02

GF Value

View ASCLF Analysis

See Total Debt per Share data for all stocks →